At a glance
ClinicalIndex Comparison RecordPhase 2Active· 81 enrolled
Drug / intervention
Aspirin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention
In Brief
A Phase 2 clinical trial evaluating Aspirin, Biospecimen Collection, and 3 other interventions for Colorectal Adenoma and Colorectal Carcinoma. Active but no longer recruiting, targeting 81 participants across 1 site.
Detailed Summary
This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Adenoma, Colorectal Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
20172018201920202021202220232024202520262027
First PostedNov 2016
Enrollment StartJan 2018
Primary CompletionJan 2023
TodayJul 2026
Study CompletionDec 2026
First PostedNov 17, 2016
Enrollment StartJan 16, 2018
Primary CompletionJan 31, 2023
Study CompletionDec 24, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.6 years ago
Interventions
Aspirindrug
Given PO
Biospecimen Collectionprocedure
Undergo collection of blood, urine, stool, and rectal swab samples
Placebo Administrationother
Given PO
Questionnaire Administrationother
Ancillary studies
Rectal Biopsyprocedure
Undergo rectal biopsy